Comparing AN69ST and PS membranes for blood purification in children with sepsis
Official title: The Effects of a AN69ST Membrane and Polysulphone Membrane on Septic Children With Continuous Blood Purification
Run by Children's Hospital of Fudan University · NCT05692011 · Data updated 2026-11-12
This compares AN69ST and PS membranes during blood purification to see if one helps children with sepsis recover better.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 29 Days to 28 Years |
| Sex | All |
| Enrollment | 80 (estimated) |
| Sponsor | Children's Hospital of Fudan University Academic / other |
| Locations | 1 site (Shanghai, Shanghai Municipality) |
| Status | Recruiting |
| Started | October 1, 2025 |
| Main results expected | December 31, 2026 |
| Study ends | December 31, 2026 |
| Registry record updated | February 17, 2026 |
| Trial ID | NCT05692011 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Children aged 29 days to 18 years with sepsis causing dysfunction of more than one organ or septic shock diagnosed within 48 hours and who are eligible for blood purification are ideal candidates.
✕Probably not a fit
Patients unlikely to benefit include those on chronic dialysis for end-stage renal disease, with non-septic shock, uncontrolled hemorrhage, severe immunodeficiency, recent chemoradiotherapy or immunosuppression, extensive recent burns, heparin allergy, or those unable to consent or present more than 48 hours after diagnosis.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This is a prospective cohort study comparing two blood purification membrane types (AN69ST versus PS) in children with sepsis who require continuous blood purification. Eligible patients are aged 29 days to 18 years with sepsis-induced multi-organ dysfunction or septic shock diagnosed within 48 hours. The study will follow clinical outcomes and inflammatory markers to compare efficacy and prognosis between the two membrane groups. Because randomized pediatric trials are scarce, this observational approach aims to generate evidence to guide membrane choice in pediatric critical care.
Why it matters
Potential benefit: If successful, the results could identify which membrane better reduces inflammation and improves recovery and prognosis in children receiving blood purification for sepsis.
How similar studies have gone: Adult studies and some pediatric observational reports suggest blood purification can lower cytokines and improve hemodynamics, but randomized data in children comparing membrane types are very limited.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Meet the 2005 diagnostic criteria for sepsis * Age 29 days - 18 years old * Sepsis-induced dysfunction of more than one organ or abnormal tissue perfusion, or septic shock * Diagnosis \< 48 hours Exclusion Criteria: * Inability to obtain an informed consent from the subject, family member or an authorized surrogate * Subject has end-stage renal disease and requires chronic dialysis * There is clinical support for non-septic shock * Subject has had chest compressions as part of cardiopulmonary resuscitation this hospitalization without immediate return to communicative state * Subject has uncontrolled hemorrhage * Subject has immunodeficiency diseases * Subject has received chemoradiotherapy or immunosuppressive therapy in the 14 days before enrollment * HIV infection in association with a last known or suspected CD4 count of \<50/mm3 * Subject has sustained extensive third-degree burns within the past 7 days * Subject has known sensitivity or allergy to heparin or has a history of heparin associated thrombocytopenia * Subject is currently enrolled in an investigational drug or device trial * Subject has been previously enrolled in the current trial * Any other condition, that in the opinion of the investigator, would preclude the subject from being a suitable candidate for enrollment, such as end stage chronic illness with no reasonable expectation of survival to hospital discharge * Known hypersensitivity to hemofilter * Subject has received organ transplantation * Subject is expected to die within 24 hours
Where it's running
-
Children's Hospital of Fudan University
Shanghai, Shanghai Municipality, China Recruiting
Study contacts
- Study coordinator: Jiayun Ying
- Email: jiayundoctor@163.com
- Phone: 18817583962
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Ruta C and Vitamin C in Sepsis: Adding antioxidants to standard care
This trial tests whether adding Ruta C (rutin plus vitamin C) or vitamin C alone to standard sepsis treatment helps adults in the ICU stay shorter and recover better.
-
Early detection of sepsis-related blood clotting problems in severe burn patients
This study tests how well the JAAM-2 score can detect sepsis-induced coagulopathy early in adults with severe burns who develop sepsis in the ICU.
-
Neutrophil EMR3 as a biomarker for sepsis in ICU patients
Researchers will test whether measuring EMR3 on neutrophils helps diagnose sepsis, monitor progression, and predict outcomes in adults in Chinese ICUs.
-
Thymalfasin added to standard care for adults with sepsis and immune dysfunction
This study tests whether thymosin alpha-1 helps restore immune function in adults with sepsis who have weakened immunity.
-
Multicenter group study of sepsis and ARDS in China
This study tests how sepsis and ARDS differ among adults across several Chinese hospitals and builds a biobank to understand why some patients do better or worse.
-
Non-invasive hemodynamic guidance for sepsis care on medical wards
This trial tests whether guiding fluid and vasopressor therapy for sepsis using non-invasive hemodynamic measurements works better than standard care.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.